Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Melodiol Global Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Melodiol Global Health şirketinin toplam hissedar öz sermayesi A$-4.1M ve toplam borcu A$9.4M olup, bu da borç-öz sermaye oranını -232% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$19.0M ve A$23.1M dir.

Anahtar bilgiler

-232.0%

Borç/özkaynak oranı

AU$9.41m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$692.00k
Eşitlik	-AU$4.06m
Toplam yükümlülükler	AU$23.10m
Toplam varlıklar	AU$19.04m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ME1 negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: ME1 şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ME1 negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: ME1 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ME1 şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: ME1 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Melodiol Global Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.45 loss in FY 2022)

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Less than half of directors are independent

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021)

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Less than half of directors are independent

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019)

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million.

Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol

Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM

Creso Pharma Limited Announces TGA Decision to Reschedule CBD

New 90-day high: AU$0.24

Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products

Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa

Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding

First half earnings released

Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin